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It is critical that LV function, both systolic and diastolic, be
measured in every patient with heart failure. The advent of tissue
Doppler (and other echo-Doppler techniques) has made it easier
and more practical to identify abnormalities in diastolic function.
Nonetheless, precise and comprehensive assessment of diastolic
function requires the use of invasive catheterization techniques.
However, if noncardiac and other cardiac causes of heart failure are
excluded, the remaining patients with heart failure and a normal
EF all have abnormalities of diastolic function making measure-
ment of diastolic function confirmatory rather than a mandatory
component of diagnostic criteria.
Finally, I join Dr. Kessler in his enthusiastic use of the term
“diastolic heart failure” and renew my editorial plea: “Stop the
discrimination against the term diastolic heart failure.”
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Determination of the Natural
History of Aspirin Resistance Among
Stable Patients With Cardiovascular Disease
We read with interest the recent study by Gum et al. (1) regarding
aspirin resistance. Their results, in particular the focus on long-
term follow-up, offer important information in the confusing but
clinically important area of aspirin resistance. They were able to
show that, by using standard light-transmittance aggregometry in
a population of patients already on aspirin therapy, the response to
two different platelet agonists could predict long-term outcome.
However, in these investigators’ original study of baseline aspirin
responsiveness in this identical patient population, a point-of-care
test, the platelet function analyzer (PFA)-100, was also used to
determine aspirin responsiveness along with light transmittance
aggregometry (2). In the first study, minimal correlation between
the two methods was found. It is unclear to us, though, why
long-term outcomes based on baseline aspirin responsiveness as
determined by the PFA-100 were not also included in their present
report. Clearly the routine determination of aspirin responsiveness
will depend upon the ability to measure it with a point-of-care
device. Therefore, whether or not the PFA-100 results correlated
with long-term clinical outcomes would have important implica-
tions regarding its utility in that role. The importance of this
question is highlighted in the editorial following the Gum et al. (3)
study as well as in a recent review of the topic, as both suggest that
the PFA-100 may be well suited for the routine determination of
aspirin resistance (3,4). However, this would likely not be the case
if PFA-100 results were found to not have any clinical relevance in
terms of future thrombotic events.
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REPLY
We appreciate and share the interest of Dr. Varinasi and colleagues
in aspirin resistance and its clinical relevance. Previously, we
documented the profile and prevalence of aspirin resistance in
stable patients with cardiovascular disease (1). In this initial study,
we used both optical platelet aggregation, which we consider to be
the gold standard for the determination of platelet reactivity in the
presence of aspirin, and a rapid, whole-blood assay, the platelet
function analyzer (PFA)-100, to determine the prevalence of
aspirin resistance. The kappa statistic between these two methods
was 0.1 (95% confidence interval 0.045 to 0.246), indicating a poor
correlation between optical platelet aggregation and the PFA-100
in detection of aspirin resistance.
In our more recently published work (2), we reported an
increased risk of death, myocardial infarction (MI), or stroke
associated with aspirin resistance as determined by optical platelet
aggregation. In analysis, long-term outcomes (death/MI/stroke)
were not related to aspirin resistance status as determined by the
PFA-100 (12.9% aspirin sensitive vs. 15.1% aspirin resistant, p 
0.4). These findings seem to indicate that the PFA-100 is not as
specific a test as compared to optical platelet aggregation for
determining clinically relevant aspirin resistance. In fact, this
supposition may be supported by the poor kappa statistic between
the two tests. However, prior to categorically drawing this conclu-
sion, one must acknowledge the real possibility of a type II error.
Although there may be no statistical association between the
PFA-100 and clinical outcomes in our investigation, a real asso-
ciation may have been missed by the small sample size of our study.
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As reported, our study did demonstrate aspirin resistance as
measured by optical platelet aggregation to be independently
predictive of poor long-term outcomes, but further work is needed
in this area. Larger studies evaluating more widely available
point-of-care tests are needed to define a test that has both ease of
use and clinical relevance.
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